KRAS (Kirsten rat sarcoma virus oncogene homologue) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals …

The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers.

Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the …

Nov 28, 2025 · In this review, we provide a brief overview of KRAS mutations in cancers and tumorigenesis, specifically focusing on currently approved therapies for targeting KRAS, …

6 days ago · 2. Frequencies and Types of KRAS Mutations KRAS mutations are widely distributed across human cancers, with approximately 11.6% of all carcinomas and 25% of tumors …

Jan 13, 2025 · In this review, we aim to summarize current knowledge on KRAS-related metabolic alterations in cancer cells and explore the prevalence and significance of KRAS mutation in …

Jul 22, 2025 · KRAS is one of the most frequently mutated oncogenes found in cancer. In healthy cells, KRAS serves as an on-off switch that regulates cell growth. However, when the gene is …

4 days ago · Zoldonrasib has received breakthrough therapy designation in pretreated KRAS G12D-mutated locally advanced or metastatic NSCLC.

3 days ago · The FDA has granted breakthrough therapy designation to zoldonrasib (RMC-9805), an investigational RAS (ON) KRAS G12D inhibitor, as a treatment for adults with locally …

Dec 31, 2025 · KRAS, which plays a critical role in cell growth and division, is mutated in roughly 30% of NSCLC cases, often leading to shorter survival and resistance to existing therapies. …